

Martin KÄŕbel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561425/publications.pdf>

Version: 2024-02-01

216
papers

14,428
citations

17440

63
h-index

23533

111
g-index

227
all docs

227
docs citations

227
times ranked

14126
citing authors

#	ARTICLE	IF	CITATIONS
1	Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma. International Journal of Gynecological Pathology, 2022, 41, 35-39.	1.4	2
2	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2022, 41, 168-179.	1.4	9
3	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. International Journal of Gynecological Pathology, 2022, 41, 12-19.	1.4	10
4	The utility of color normalization for AI-based diagnosis of hematoxylin and eosin-stained pathology images. Journal of Pathology, 2022, 256, 15-24.	4.5	19
5	Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features. Journal of Pathology: Clinical Research, 2022, 8, 19-32.	3.0	15
6	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 132-141.	2.5	12
7	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	2.8	8
8	The Evolution of Ovarian Carcinoma Subclassification. Cancers, 2022, 14, 416.	3.7	38
9	Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. Journal of Gynecologic Oncology, 2022, 33, .	2.2	5
10	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 ⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
11	Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract. Journal of Pathology, 2022, 257, 140-145.	4.5	9
12	Endometrial neuroendocrine carcinoma and undifferentiated carcinoma are distinct entities with overlap in neuroendocrine marker expression. Histopathology, 2022, 81, 44-54.	2.9	6
13	Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. American Journal of Surgical Pathology, 2022, 46, 1142-1152.	3.7	10
14	Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes. Fertility and Sterility, 2022, 118, 524-534.	1.0	12
15	Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. Npj Precision Oncology, 2022, 6, .	5.4	9
16	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clinical Cancer Research, 2022, 28, 4947-4956.	7.0	22
17	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
18	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	5.5	21

#	ARTICLE	IF	CITATIONS
19	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. <i>Modern Pathology</i> , 2021, 34, 1008-1016.	5.5	27
20	<scp>SWI</scp></scp><scp>SNF</scp></scp> deficiency defines highly aggressive undifferentiated endometrial carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 144-153.	3.0	38
21	p53 immunohistochemical analysis of fusion-positive uterine sarcomas. <i>Histopathology</i> , 2021, 78, 805-813.	2.9	17
22	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , 2021, 253, 41-54.	4.5	54
23	Embryonic protein NODAL regulates the breast tumor microenvironment by reprogramming cancer-derived secretomes. <i>Neoplasia</i> , 2021, 23, 375-390.	5.3	3
24	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	4.1	62
25	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021, 125, 265-276.	6.4	7
26	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5325.	4.1	16
27	Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. <i>Gynecologic Oncology</i> , 2021, 161, 342-346.	1.4	7
28	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021, 42, 785-793.	2.8	6
29	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100042.	1.7	6
30	Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix. <i>Histopathology</i> , 2021, 79, 160-167.	2.9	10
31	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2021, 162, 421-430.	1.4	10
32	Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1452-1463.	3.7	10
33	Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 116-123.	1.4	36
34	The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 32-40.	1.4	37
35	Adenocarcinoma of the Uterine Cervix: Immunohistochemical Biomarker Expression and Diagnostic Performance. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 209-217.	1.2	1
36	Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15 years. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100890.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Testing Algorithms for the Diagnosis of Malignant Glandular Tumors of the Uterine Cervix Histotyped per the International Endocervical Adenocarcinoma Criteria and Classification (IECC) System. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, .	1.2	0
38	Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease – Report of six rare and unique cases. Annals of Diagnostic Pathology, 2020, 44, 151455.	1.3	7
39	Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 552-560.	1.4	49
40	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. International Journal of Gynecological Pathology, 2020, 39, 537-545.	1.4	25
41	p53 immunohistochemistry is an accurate surrogate for <i>TP53</i> mutational analysis in endometrial carcinoma biopsies. Journal of Pathology, 2020, 250, 336-345.	4.5	164
42	Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America. Diagnostic Pathology, 2020, 15, 86.	2.0	3
43	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin. , 2020, 8, e001128.		14
44	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	7.0	41
45	Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases. Journal of Clinical Pathology, 2020, 73, 391-402.	2.0	29
46	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. Journal of Pathology: Clinical Research, 2020, 6, 252-262.	3.0	33
47	Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. Histopathology, 2020, 77, 46-54.	2.9	39
48	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
49	Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to T Cell Cytotoxicity. Frontiers in Immunology, 2020, 11, 1287.	4.8	10
50	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. Modern Pathology, 2020, 33, 2361-2377.	5.5	4
51	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
52	PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecologic Oncology, 2020, 158, 776-784.	1.4	15
53	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. Gynecologic Oncology, 2020, 157, 36-45.	1.4	9
54	The MOCOG study: Learning from extraordinary responders to improve treatment outcomes for women with ovarian cancer. Pathology, 2020, 52, S30-S31.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 12-20.	1.4	18
56	High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. <i>Human Pathology</i> , 2020, 98, 56-63.	2.0	7
57	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , 2020, 15, e0240412.	2.5	1
58	Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. <i>Current Drug Targets</i> , 2020, 21, 974-995.	2.1	3
59	Title is missing!. , 2020, 15, e0240412.		0
60	Title is missing!. , 2020, 15, e0240412.		0
61	Title is missing!. , 2020, 15, e0240412.		0
62	Title is missing!. , 2020, 15, e0240412.		0
63	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 353-362.	1.4	45
64	FIGO Stage Is the Strongest Prognostic Factor in Adenocarcinoma of the Uterine Cervix. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1318-1324.	0.7	9
65	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	12.8	110
66	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
67	Oncogenic mutations in histologically normal endometrium: the new normal?. <i>Journal of Pathology</i> , 2019, 249, 173-181.	4.5	106
68	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019, 25, 3962-3973.	7.0	36
69	Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4309-4319.	7.0	33
70	A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 177-188.	3.0	11
71	Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon. <i>American Journal of Surgical Pathology</i> , 2019, 43, 531-537.	3.7	24
72	Ovarian Endometrioid Carcinoma Misdiagnosed as Mucinous Carcinoma: An Underrecognized Problem. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 568-575.	1.4	17

#	ARTICLE	IF	CITATIONS
73	Genomic Applications in Ovarian Cancer. , 2019, , 471-482.		0
74	Prognostic value of progesterone receptor expression in tuboovarian high-grade serous carcinoma of the COEUR cohort. Histopathology, 2019, 74, 663-666.	2.9	3
75	Nuclear β -catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome. Histopathology, 2019, 74, 452-462.	2.9	29
76	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. International Journal of Gynecological Pathology, 2019, 38, 119-127.	1.4	10
77	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. International Journal of Gynecological Pathology, 2019, 38, S123-S131.	1.4	226
78	Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. Journal of the National Cancer Institute, 2019, 111, 60-68.	6.3	319
79	Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma. Frontiers in Oncology, 2019, 9, 1570.	2.8	24
80	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
81	Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-549. Journal of Pathology, 2018, 245, 249-250.	4.5	13
82	Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. Journal of Lower Genital Tract Disease, 2018, 22, 132-138.	1.9	4
83	Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. Histopathology, 2018, 73, 299-305.	2.9	25
84	High-grade Endometrioid Carcinoma of the Ovary. American Journal of Surgical Pathology, 2018, 42, 534-544.	3.7	34
85	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	2.6	67
86	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	7.0	79
87	Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins. American Journal of Surgical Pathology, 2018, 42, 76-83.	3.7	78
88	ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus. American Journal of Surgical Pathology, 2018, 42, 1353-1359.	3.7	48
89	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
90	You won't believe this old test that does cheap single-cell mutation detection. Journal of Pathology: Clinical Research, 2018, 4, 149-153.	3.0	14

#	ARTICLE	IF	CITATIONS
91	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , 2018, 151, 53-60.	1.4	54
92	Immunohistochemical Profiling of Endometrial Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 128-139.	1.4	54
93	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. <i>Modern Pathology</i> , 2017, 30, 577-586.	5.5	132
94	Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles. <i>Cancer Causes and Control</i> , 2017, 28, 447-457.	1.8	20
95	Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2017, 41, 685-695.	3.7	70
96	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 555-561.	1.4	40
97	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , 2017, 41, 245-252.	3.7	81
98	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
99	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017, 28, 459-468.	1.8	20
100	Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk. <i>British Journal of Cancer</i> , 2017, 116, 265-269.	6.4	8
101	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 279-293.	3.0	70
102	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
103	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
104	Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 214-222.	2.5	4
105	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , 2017, 77, 4268-4278.	0.9	56
106	Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma. <i>Histopathology</i> , 2017, 70, 347-358.	2.9	24
107	Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 515.	4.1	32
108	A comparison of p53 and <i>WT1</i> immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. <i>Histopathology</i> , 2017, 71, 736-742.	2.9	27

#	ARTICLE	IF	CITATIONS
109	Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. <i>Histopathology</i> , 2016, 69, 288-297.	2.9	77
110	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 209-221.	1.4	28
111	Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from microRNA-141 deficient tumours. <i>Histopathology</i> , 2016, 69, 560-569.	2.9	54
112	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	1.4	25
113	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. <i>Modern Pathology</i> , 2016, 29, 1586-1593.	5.5	87
114	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , 2016, 143, 46-53.	1.4	153
115	Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 247-258.	3.0	280
116	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. <i>Cancer Epidemiology</i> , 2016, 45, 119-125.	1.9	20
117	Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study. <i>Gynecologic Oncology</i> , 2016, 140, 277-284.	1.4	20
118	Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 431-436.	2.5	29
119	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 430-441.	1.4	180
120	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	1.4	34
121	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 302-314.	5.5	123
122	Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 124-130.	1.4	42
123	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. <i>Histopathology</i> , 2016, 68, 916-924.	2.9	65
124	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. <i>American Journal of Surgical Pathology</i> , 2016, 40, 166-180.	3.7	51
125	Disseminated Mycobacterium kansasii Infection in a Patient With Silicosis, Pulmonary Alveolar Proteinosis, and Myelodysplastic Syndrome. <i>Chest</i> , 2015, 148, 154A.	0.8	0
126	Endometrial Carcinomas With Clear Cells. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 323-333.	1.4	44

#	ARTICLE	IF	CITATIONS
127	Efficient molecular subtype classification of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2015, 236, 272-277.	4.5	81
128	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 517-527.	1.4	15
129	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1548-1557.	3.7	70
130	Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases. <i>American Journal of Surgical Pathology</i> , 2015, 39, 357-364.	3.7	104
131	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1187-1193.	2.5	31
132	Targeted mutation analysis of endometrial clear cell carcinoma. <i>Histopathology</i> , 2015, 66, 664-674.	2.9	77
133	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	1.4	50
134	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. <i>Modern Pathology</i> , 2015, 28, 505-514.	5.5	180
135	Biobanking in the Twenty-First Century: Driving Population Metrics into Biobanking Quality. <i>Advances in Experimental Medicine and Biology</i> , 2015, 864, 95-114.	1.6	9
136	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2015, 6, 39088-39097.	1.8	67
137	Low-Grade Serous Carcinoma – The Clinical Challenge. <i>Gynecology and Obstetrics Research: Open Journal</i> , 2015, 2, 35-40.	1.6	0
138	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. <i>British Journal of Cancer</i> , 2014, 111, 2297-2307.	6.4	76
139	Napsin A. <i>American Journal of Clinical Pathology</i> , 2014, 142, 735-737.	0.7	14
140	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma – diagnostic utility of HNF1 β and oestrogen receptor. <i>Histopathology</i> , 2014, 64, 585-596.	2.9	68
141	PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 188-193.	1.4	24
142	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. <i>Histopathology</i> , 2014, 64, 1004-1013.	2.9	104
143	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2014, 134, 15-19.	1.4	159
144	New Views of Ovarian Carcinoma Types: How Will This Change Practice?. , 2014, , 29-38.		1

#	ARTICLE	IF	CITATIONS
145	Abstract 1535: Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma. <i>Cancer Research</i> , 2014, 74, 1535-1535.	0.9	2
146	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. <i>BMC Cancer</i> , 2013, 13, 28.	2.6	28
147	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
148	Reproducibility of histological cell type in high-grade endometrial carcinoma. <i>Modern Pathology</i> , 2013, 26, 1594-1604.	5.5	167
149	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. <i>Modern Pathology</i> , 2013, 26, 1255-1263.	5.5	52
150	MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. <i>Gynecologic Oncology</i> , 2013, 131, 309-314.	1.4	49
151	PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. <i>Gynecologic Oncology</i> , 2013, 128, 409-414.	1.4	99
152	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. <i>Biopreservation and Biobanking</i> , 2013, 11, 83-93.	1.0	35
153	Quantification of ER/PR expression in ovarian low-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 371-376.	1.4	63
154	A rare case of NUT midline carcinoma. <i>Gynecologic Oncology Case Reports</i> , 2013, 3, 1-3.	0.9	22
155	Differentially Methylated Loci Distinguish Ovarian Carcinoma Histological Types: Evaluation of a DNA Methylation Assay in FFPE Tissue. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	8
156	Re. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 176.	1.4	0
157	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1421-1432.	3.7	115
158	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1677-1686.	2.5	70
159	Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (<sc>COSP</sc>) is a reliable high-throughput tool for case review. <i>Histopathology</i> , 2013, 63, 704-712.	2.9	5
160	Re: <i>Biopreserv Biobank</i> 11:83-93. <i>Biopreservation and Biobanking</i> , 2013, 11, 257-257.	1.0	1
161	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
162	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 517-25.	8.2	462

#	ARTICLE	IF	CITATIONS
163	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	5.5	151
164	Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 397-404.	1.4	25
165	Type-Specific Response to Neoadjuvant Chemotherapy: Ovarian High-Grade Serous Carcinoma Versus Colorectal Mucinous Carcinoma. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 678-682.	0.7	4
166	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012, 10, 33.	4.4	93
167	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 239-252.	3.3	50
168	Molecular Pathology of Ovarian Carcinomas. <i>Surgical Pathology Clinics</i> , 2011, 4, 275-296.	1.7	1
169	Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. <i>Lancet Oncology</i> , 2011, 12, 1071-1080.	10.7	127
170	Biomarker Expression in Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 366-371.	1.4	34
171	Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 36-44.	3.7	129
172	Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. <i>Gynecologic Oncology</i> , 2011, 121, 407-415.	1.4	225
173	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011, 24, 512-521.	5.5	95
174	Letter to the editor regarding "Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression". <i>Modern Pathology</i> , 2011, 24, 1281-1282.	5.5	6
175	Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. <i>Annals of Oncology</i> , 2011, 22, 341-347.	1.2	64
176	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. <i>American Journal of Surgical Pathology</i> , 2010, 34, 984-993.	3.7	143
177	Tumor Type and Substage Predict Survival in Stage I and II Ovarian Carcinoma: Insights and Implications. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 232-234.	0.4	0
178	Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 99-107.	1.4	90
179	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 203-211.	1.4	332
180	High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 343-350.	1.4	146

#	ARTICLE	IF	CITATIONS
181	Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. <i>Gynecologic Oncology</i> , 2010, 116, 50-56.	1.4	129
182	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. <i>Journal of Pathology</i> , 2010, 220, 392-400.	4.5	92
183	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. <i>Journal of Pathology</i> , 2010, 222, 191-198.	4.5	136
184	Genetic Variation in <i>TYMS</i> in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1822-1830.	2.5	24
185	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. <i>PLoS ONE</i> , 2009, 4, e6412.	2.5	354
186	Adult-Type Granulosa Cell Tumors and FOXL2 Mutation. <i>Cancer Research</i> , 2009, 69, 9160-9162.	0.9	58
187	Dicer and Drosha in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 1150-1151.	27.0	8
188	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. <i>BMC Cancer</i> , 2009, 9, 433.	2.6	175
189	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , 2009, 22, 469-475.	5.5	125
190	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	27.0	706
191	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2009, 33, 14-21.	3.7	211
192	Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 375-382.	1.2	32
193	The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 58-64.	2.5	181
194	Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. <i>Neoplasia</i> , 2008, 10, 1021-1027.	5.3	158
195	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008, 39, 1239-1251.	2.0	231
196	Critical molecular abnormalities in high-grade serous carcinoma of the ovary. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e22.	3.9	48
197	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e3409.	2.5	37
198	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. <i>PLoS Medicine</i> , 2008, 5, e232.	8.4	675

#	ARTICLE	IF	CITATIONS
199	Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. <i>International Journal of Cancer</i> , 2007, 120, 2393-2400.	5.1	20
200	Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. <i>Oncogene</i> , 2007, 26, 7584-7589.	5.9	101
201	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , 2007, 5, 33.	5.5	52
202	Ezrin Promotes Ovarian Carcinoma Cell Invasion and Its Retained Expression Predicts Poor Prognosis in Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 121-130.	1.4	59
203	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. <i>Modern Pathology</i> , 2006, 19, 581-587.	5.5	52
204	Expression of lysophosphatidic acid acyltransferase beta (LPAAT- β) in ovarian carcinoma: correlation with tumour grading and prognosis. <i>British Journal of Cancer</i> , 2005, 92, 1729-1736.	6.4	25
205	Influence of Various Cytokines on Adhesion and Migration of the Colorectal Adenocarcinoma Cell Line HRT-18. <i>Oncology</i> , 2005, 68, 33-39.	1.9	6
206	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. <i>American Journal of Pathology</i> , 2005, 167, 879-885.	3.8	27
207	Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation. <i>Anticancer Research</i> , 2005, 25, 3431-6.	1.1	13
208	Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression. <i>Cancer Research</i> , 2004, 64, 189-195.	0.9	153
209	Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. <i>British Journal of Cancer</i> , 2004, 90, 815-821.	6.4	157
210	Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 456-464.	2.8	61
211	Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. <i>Cancer</i> , 2003, 97, 2978-2987.	4.1	197
212	Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. <i>Oncogene</i> , 2003, 22, 8653-8661.	5.9	90
213	Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. <i>European Journal of Cell Biology</i> , 2003, 82, 1-8.	3.6	28
214	Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. <i>Cancer Letters</i> , 2003, 195, 101-109.	7.2	17
215	Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2002, 160, 893-903.	3.8	183
216	Interleukin-10 in serous ovarian carcinoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 328-333.	4.2	24